Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Eun Seok Kang  (Kang ES) 22 Articles
Miscellaneous
Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
Ji Young Lee, Minyoung Lee, Dong-Hee Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Endocrinol Metab. 2022;37(4):684-697.   Published online August 29, 2022
DOI: https://doi.org/10.3803/EnM.2022.1446
  • 2,147 View
  • 107 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Muscle atrophy is caused by an imbalance between muscle growth and wasting. Delta-like 1 homolog (DLK1), a protein that modulates adipogenesis and muscle development, is a crucial regulator of myogenic programming. Thus, we investigated the effect of exogenous DLK1 on muscular atrophy.
Methods
We used muscular atrophy mouse model induced by dexamethasone (Dex). The mice were randomly divided into three groups: (1) control group, (2) Dex-induced muscle atrophy group, and (3) Dex-induced muscle atrophy group treated with DLK1. The effects of DLK1 were also investigated in an in vitro model using C2C12 myotubes.
Results
Dex-induced muscular atrophy in mice was associated with increased expression of muscle atrophy markers and decreased expression of muscle differentiation markers, while DLK1 treatment attenuated these degenerative changes together with reduced expression of the muscle growth inhibitor, myostatin. In addition, electron microscopy revealed that DLK1 treatment improved mitochondrial dynamics in the Dex-induced atrophy model. In the in vitro model of muscle atrophy, normalized expression of muscle differentiation markers by DLK1 treatment was mitigated by myostatin knockdown, implying that DLK1 attenuates muscle atrophy through the myostatin pathway.
Conclusion
DLK1 treatment inhibited muscular atrophy by suppressing myostatin-driven signaling and improving mitochondrial biogenesis. Thus, DLK1 might be a promising candidate to treat sarcopenia, characterized by muscle atrophy and degeneration.
Diabetes, Obesity and Metabolism
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinol Metab. 2021;36(4):823-834.   Published online August 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1074
  • 3,406 View
  • 121 Download
  • 1 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Type 2 diabetes mellitus (T2DM) is a risk factor that accelerates NAFLD progression, leading to fibrosis and cirrhosis. Thus, here we aimed to develop a simple model to predict the presence of NAFLD based on clinical parameters of patients with T2DM.
Methods
A total of 698 patients with T2DM who visited five medical centers were included. NAFLD was evaluated using transient elastography. Univariate logistic regression analyses were performed to identify potential contributors to NAFLD, followed by multivariable logistic regression analyses to create the final prediction model for NAFLD.
Results
Two NAFLD prediction models were developed, with and without serum biomarker use. The non-laboratory model comprised six variables: age, sex, waist circumference, body mass index (BMI), dyslipidemia, and smoking status. For a cutoff value of ≥60, the prediction accuracy was 0.780 (95% confidence interval [CI], 0.743 to 0.817). The second comprehensive model showed an improved discrimination ability of up to 0.815 (95% CI, 0.782 to 0.847) and comprised seven variables: age, sex, waist circumference, BMI, glycated hemoglobin, triglyceride, and alanine aminotransferase to aspartate aminotransferase ratio. Our non-laboratory model showed non-inferiority in the prediction of NAFLD versus previously established models, including serum parameters.
Conclusion
The new models are simple and user-friendly screening methods that can identify individuals with T2DM who are at high-risk for NAFLD. Additional studies are warranted to validate these new models as useful predictive tools for NAFLD in clinical practice.

Citations

Citations to this article as recorded by  
  • Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
    Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
    Biomedicines.2023; 11(4): 1097.     CrossRef
Clinical Study
Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
Da Hea Seo, Shinae Kang, Yong-ho Lee, Jung Yoon Ha, Jong Suk Park, Byoung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong-Soo Cha
Endocrinol Metab. 2019;34(3):282-290.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.282
  • 5,152 View
  • 74 Download
  • 13 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background

This study investigated the overall status of diabetes control and screening for diabetic microvascular complications in patients with type 2 diabetes mellitus attending primary care clinics in Korea.

Methods

In this cross-sectional observational study, 191 primary care clinics were randomly selected across Korea from 2015 to 2016. In total, 3,227 subjects were enrolled in the study.

Results

The patients followed at the primary care clinics were relatively young, with a mean age of 61.4±11.7 years, and had a relatively short duration of diabetes (mean duration, 7.6±6.5 years). Approximately 14% of subjects had diabetic microvascular complications. However, the patients treated at the primary care clinics had suboptimal control of hemoglobin A1c levels, blood pressure, and serum lipid levels, along with a metabolic target achievement rate of 5.9% according to the Korean Diabetes Association guidelines. The screening rates for diabetic nephropathy, retinopathy, and neuropathy within the past 12 months were 28.4%, 23.3%, and 13.3%, respectively.

Conclusion

The overall status of diabetes management, including the frequency of screening for microvascular complications, was suboptimal in the primary care clinics. More efforts should be made and more resources need to be allocated for primary care physicians to promote adequate healthcare delivery, which would result in stricter diabetes control and improved management of diabetic complications.

Citations

Citations to this article as recorded by  
  • Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM)
    Chun Cai, Yuexing Liu, Yanyun Li, Yan Shi, Haidong Zou, Yuqian Bao, Yun Shen, Xin Cui, Chen Fu, Weiping Jia
    Frontiers of Medicine.2022; 16(1): 126.     CrossRef
  • Comparison of Health Outcomes by Care Provider Type for Newly Diagnosed Mild Type 2 Diabetes Patients in South Korea: A Retrospective Cohort Study
    Hee-Chung Kang, Jae-Seok Hong
    Healthcare.2022; 10(2): 334.     CrossRef
  • Management Status of Patients with Type 2 Diabetes Mellitus at General Hospitals in Korea: A 5-Year Follow-Up Study
    Jin Hee Jung, Jung Hwa Lee, Hyang Mi Jang, Young Na, Hee Sun Choi, Yeon Hee Lee, Yang Gyo Kang, Na Rae Kim, Jeong Rim Lee, Bok Rye Song, Kang Hee Sim
    The Journal of Korean Diabetes.2022; 23(1): 64.     CrossRef
  • Type 2 Diabetes Mellitus with Early Dry Skin Disorder: A Comparison Study Between Primary and Tertiary Care in Indonesia
    Lili Legiawati, Kusmarinah Bramono, Wresti Indriatmi, Em Yunir, Aditya Indra Pratama
    Current Diabetes Reviews.2022;[Epub]     CrossRef
  • Long-Term Changes in HbA1c According to Blood Glucose Control Status During the First 3 Months After Visiting a Tertiary University Hospital
    Hyunah Kim, Da Young Jung, Seung-Hwan Lee, Jae-Hyoung Cho, Hyeon Woo Yim, Hun-Sung Kim
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Differences in health behavior and nutrient intake status between diabetes-aware and unaware Korean adults based on the Korea national health and nutrition examination survey 2016–18 data: A cross-sectional study
    Anshul Sharma, Chen Lulu, Kee-Ho Song, Hae-Jeung Lee
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Effects of Diabetes Quality Assessment on Diabetes Management Behaviors Based on a Nationwide Survey
    Chang Kyun Choi, Jungho Yang, Ji-An Jeong, Min-Ho Shin
    International Journal of Environmental Research and Public Health.2022; 19(23): 15781.     CrossRef
  • The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting
    Firas Farisi Alkaff, Fauzan Illavi, Sovia Salamah, Wiwit Setiyawati, Ristra Ramadhani, Elly Purwantini, Dicky L. Tahapary
    Journal of Primary Care & Community Health.2021; 12: 215013272098440.     CrossRef
  • Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-Onset Diabetes
    Ji In Park, Hyunjeong Baek, Sang-Wook Kim, Ji Yun Jeong, Kee-Ho Song, Ji Hee Yu, Il Sung Nam-Goong, Eun-Hee Cho
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
    Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
    Diabetes Care.2021; 44(10): 2419.     CrossRef
  • Challenges in the Management of Diabetes in Primary Care
    Yeon Kyung Lee
    The Journal of Korean Diabetes.2020; 21(3): 161.     CrossRef
  • Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
    Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
    Diabetes & Metabolism Journal.2020; 44(6): 897.     CrossRef
  • Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
    Chan-Hee Jung
    Endocrinology and Metabolism.2019; 34(3): 265.     CrossRef
Obesity and Metabolism
Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis
Namki Hong, Yong-ho Lee, Kenichi Tsujita, Jorge A. Gonzalez, Christopher M. Kramer, Tomas Kovarnik, George N. Kouvelos, Hiromichi Suzuki, Kyungdo Han, Chan Joo Lee, Sung Ha Park, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinol Metab. 2018;33(2):219-227.   Published online May 4, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.219
  • 4,610 View
  • 98 Download
  • 13 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background

Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes.

Methods

Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression.

Results

A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean follow-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct contact (five trials). No significant heterogeneity was observed among studies (I2=14.7%, P=0.293). Ezetimibe was associated with a greater reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; Pheterogeneity=0.012). In the meta-regression analysis, the presence of diabetes was associated with a greater reduction of MACE risk when ezetimibe was added to statins (β=0.87, P=0.038).

Conclusion

Ezetimibe-statin combination therapy was associated with greater cardiovascular benefits in patients with diabetes than in those without diabetes. Our findings suggest that ezetimibe-statin combination therapy might be a useful strategy in patients with diabetes at a residual risk of MACEs.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
    Kenichi Tsujita, Koutaro Yokote, Junya Ako, Ryohei Tanigawa, Sachiko Tajima, Hideki Suganami
    Journal of Atherosclerosis and Thrombosis.2023;[Epub]     CrossRef
  • Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
    Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
    BMC Medicine.2022;[Epub]     CrossRef
  • RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
    Banshi Saboo, Sanjay Agarwal, Brij Mohan Makkar, Rajeev Chawla, Sujoy Ghosh, Vijay Viswanathan, Sunil Gupta, Ch. Vasanth Kumar, Anuj Maheshwari, L. Sreenivasamurthy, Rakesh Kumar Sahay, Sanjay Reddy, Shalini Jaggi, Jugal Kishor Sharma, Vijay Panikar, Anan
    International Journal of Diabetes in Developing Countries.2022; 42(1): 3.     CrossRef
  • Ezetimibe and diabetes mellitus:a new strategy for lowering cholesterol
    V.A. Serhiyenko, A.A. Serhiyenko
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(5): 302.     CrossRef
  • 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
    Diabetes & Metabolism Journal.2021; 45(4): 461.     CrossRef
  • Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study
    You-Bin Lee, Bongsung Kim, Kyungdo Han, Jung A Kim, Eun Roh, So-hyeon Hong, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Journal of Lipid and Atherosclerosis.2021; 10(3): 303.     CrossRef
  • PCSK9 inhibitors and cardiovascular outcomes
    Daniel Steffens, Peter Bramlage, Céline Scheeff, Mario Kasner, Adel Hassanein, Julian Friebel, Ursula Rauch-Kröhnert
    Expert Opinion on Biological Therapy.2020; 20(1): 35.     CrossRef
  • Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
    Jaehyun Bae, Namki Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
    Journal of Clinical Medicine.2020; 9(3): 798.     CrossRef
  • Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue
    Yongin Cho, Ryeong-Hyeon Kim, Hyunki Park, Hye Jin Wang, Hyangkyu Lee, Eun Seok Kang
    Biomedicines.2020; 8(11): 512.     CrossRef
  • Future perspectives of the pharmacological management of diabetic dyslipidemia
    Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A. Rizvi
    Expert Review of Clinical Pharmacology.2019; 12(2): 129.     CrossRef
  • Diabetes and Vascular Disease: Is It All About Glycemia?
    Alessandra Vecchié, Fabrizio Montecucco, Federico Carbone, Franco Dallegri, Aldo Bonaventura
    Current Pharmaceutical Design.2019; 25(29): 3112.     CrossRef
  • Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
    Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
    Endocrinology and Metabolism.2018; 33(2): 195.     CrossRef
  • Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia
    Janet Fricker
    EMJ Cardiology.2018; : 38.     CrossRef
Miscellaneous
Effects of Serum Albumin, Calcium Levels, Cancer Stage and Performance Status on Weight Loss in Parathyroid Hormone-Related Peptide Positive or Negative Patients with Cancer
Ji-Yeon Lee, Namki Hong, Hye Ryun Kim, Byung Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
Endocrinol Metab. 2018;33(1):97-104.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.97
  • 3,743 View
  • 42 Download
  • 3 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   CrossRef-TDMCrossref - TDM
Background

A recent animal study showed that parathyroid hormone-related peptide (PTHrP) is associated with cancer cachexia by promoting adipose tissue browning, and we previously demonstrated that PTHrP predicts weight loss (WL) in patients with cancer. In this study, we investigated whether prediction of WL by PTHrP is influenced by clinical factors such as serum albumin, corrected calcium levels, cancer stage, and performance status (PS).

Methods

A cohort of 219 patients with cancer whose PTHrP level was measured was enrolled and followed for body weight (BW) changes. Subjects were divided into two groups by serum albumin (cutoff value, 3.7 g/dL), corrected calcium (cutoff value, 10.5 mg/dL), cancer stage (stage 1 to 3 or 4), or PS (Eastern Cooperative Oncology Group 0 to 1 or 2 to 4), respectively. Clinically significant WL was defined as either percent of BW change (% BW) <−5% or % BW <−2% plus body mass index (BMI) <20 kg/m2.

Results

After a median follow-up of 327 days, 74 patients (33.8%) experienced clinically significant WL. A positive PTHrP level was associated with a 2-fold increased risk of WL after adjusting for age, baseline BMI, serum albumin, corrected calcium level, cancer stage, and PS. The effect of PTHrP on WL remained significant in patients with low serum albumin, stage 4 cancer, and good PS. Regardless of calcium level, the effect of PTHrP on WL was maintained, although there was an additive effect of higher calcium and PTHrP levels.

Conclusion

Early recognition of patients with advanced cancer who are PTHrP positive with hypercalcemia or hypoalbuminemia is needed for their clinical management.

Citations

Citations to this article as recorded by  
  • Parathyroid hormone related protein (PTHrP) in patients with pancreatic carcinoma and overt signs of disease progression and host tissue wasting
    Britt-Marie Iresjö, Serkan Kir, Kent Lundholm
    Translational Oncology.2023; 36: 101752.     CrossRef
  • Inhibition of epidermal growth factor receptor suppresses parathyroid hormone‐related protein expression in tumours and ameliorates cancer‐associated cachexia
    Bahar Zehra Camurdanoglu Weber, Samet Agca, Aylin Domaniku, Sevval Nur Bilgic, Dilsad H. Arabaci, Serkan Kir
    Journal of Cachexia, Sarcopenia and Muscle.2022; 13(3): 1582.     CrossRef
  • Metabolic Reprogramming in Adipose Tissue During Cancer Cachexia
    Bahar Zehra Camurdanoglu Weber, Dilsad H. Arabaci, Serkan Kir
    Frontiers in Oncology.2022;[Epub]     CrossRef
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinol Metab. 2017;32(2):274-280.   Published online June 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.274
  • 4,373 View
  • 142 Download
  • 7 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM
Background

Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes.

Methods

We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a >3% reduction in eGFR in a 1-year period.

Results

In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42).

Conclusion

These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

Citations

Citations to this article as recorded by  
  • Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
    Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
    Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583.     CrossRef
  • The challenge of reducing residual cardiovascular risk in patients with chronic kidney disease
    Stefan Mark Nidorf
    European Heart Journal.2022; 43(46): 4845.     CrossRef
  • Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options
    Ahmed H. Abdelhafiz
    Drugs & Aging.2020; 37(8): 567.     CrossRef
  • Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane
    Pan-Feng Feng, Bo Zhang, Lei Zhao, Qing Fang, Yan Liu, Jun-Nan Wang, Xue-Qi Xu, Hui Xue, Yang Li, Cai-Chuan Yan, Xin Zhao, Bao-Xin Li
    Molecular Pharmaceutics.2019; 16(4): 1477.     CrossRef
  • The problem of safety of lipid-lowering therapy
    M V. Zykov
    Kardiologiia.2019; 59(5S): 13.     CrossRef
  • Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction
    Titus WL Lau, Kevin E.K. Tan, Jason C.J. Choo, Tsun‐Gun Ng, Subramaniam Tavintharan, Juliana C.N. Chan
    Journal of Diabetes.2018; 10(3): 200.     CrossRef
  • Lipids: a personal view of the past decade
    Niki Katsiki, Dimitri P Mikhailidis
    Hormones.2018; 17(4): 461.     CrossRef
Clinical Study
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang
Endocrinol Metab. 2016;31(1):161-167.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.161
  • 4,783 View
  • 56 Download
  • 18 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM
Background

The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes.

Methods

Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor.

Results

HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.

Conclusion

Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.

Citations

Citations to this article as recorded by  
  • Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
    Lee-Moay Lim, Jer-Ming Chang, Hung-Tien Kuo
    Biomedicines.2023; 11(2): 470.     CrossRef
  • Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post‐transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation
    S. Elise Lawrence, Mary Moss Chandran, Jeong M. Park, Helen Sweiss, Thomas Jensen, Palak Choksi, Barrett Crowther
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review
    Adnan Sharif
    Transplantation.2022; 106(12): 2301.     CrossRef
  • Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats
    Feng-Yen Lin, Chun-Min Shih, Chun-Yao Huang, Yi-Tin Tsai, Shih-Hurng Loh, Chi-Yuan Li, Cheng-Yen Lin, Yi-Wen Lin, Chien-Sung Tsai
    Cardiovascular Drugs and Therapy.2021; 35(6): 1111.     CrossRef
  • Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
    Sonya Anderson, Laura Cotiguala, Sarah Tischer, Jeong Mi Park, Katie McMurry
    Annals of Pharmacotherapy.2021; 55(4): 496.     CrossRef
  • Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
    Dora Oikonomaki, Evangelia Dounousi, Anila Duni, Stefanos Roumeliotis, Vassilios Liakopoulos
    Diabetes Research and Clinical Practice.2021; 172: 108604.     CrossRef
  • CD161a-positive natural killer (NK) cells and α-smooth muscle actin-positive myofibroblasts were upregulated by extrarenal DPP4 in a rat model of acute renal rejection
    Franziska Schmid, Christina Mayer, Maike Büttner-Herold, Stephan von Hörsten, Kerstin Amann, Christoph Daniel
    Diabetes Research and Clinical Practice.2021; 173: 108691.     CrossRef
  • Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients
    Theerawut Klangjareonchai, Natsuki Eguchi, Ekamol Tantisattamo, Antoney J. Ferrey, Uttam Reddy, Donald C. Dafoe, Hirohito Ichii
    Pharmaceutics.2021; 13(3): 413.     CrossRef
  • Recent advances in new-onset diabetes mellitus after kidney transplantation
    Tess Montada-Atin, G V Ramesh Prasad
    World Journal of Diabetes.2021; 12(5): 541.     CrossRef
  • Safety and Efficacy of Long-Term Administration of Dipeptidyl peptidase IV Inhibitors in Patients With New Onset Diabetes After Kidney Transplant
    Adamantia Mpratsiakou, Marios Papasotiriou, Theodoros Ntrinias, Konstantinos Tsiotsios, Evangelos Papachristou, Dimitrios S. Goumenos
    Experimental and Clinical Transplantation.2021; 19(5): 411.     CrossRef
  • Medical management of metabolic and cardiovascular complications after liver transplantation
    Chiara Becchetti, Melisa Dirchwolf, Vanessa Banz, Jean-François Dufour
    World Journal of Gastroenterology.2020; 26(18): 2138.     CrossRef
  • Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Kidney Transplant Recipients with Post-transplant Diabetes Mellitus (PTDM)- a Systematic Review and Meta-Analysis
    Tarek Samy Abdelaziz, Ahmed Yamany Ali, Moataz Fatthy
    Current Diabetes Reviews.2020; 16(6): 580.     CrossRef
  • NAFLD and liver transplantation: Disease burden, current management and future challenges
    Patrizia Burra, Chiara Becchetti, Giacomo Germani
    JHEP Reports.2020; 2(6): 100192.     CrossRef
  • Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study
    Rodolfo Guardado-Mendoza, David Cázares-Sánchez, María Lola Evia-Viscarra, Lilia M. Jiménez-Ceja, Edgar G. Durán-Pérez, Alberto Aguilar-García
    Diabetes Research and Clinical Practice.2019; 156: 107864.     CrossRef
  • Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment
    Maria J. Peláez-Jaramillo, Allison A. Cárdenas-Mojica, Paula V. Gaete, Carlos O. Mendivil
    Diabetes Therapy.2018; 9(2): 521.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus
    Thomas Vanhove, Quinten Remijsen, Dirk Kuypers, Pieter Gillard
    Transplantation Reviews.2017; 31(2): 69.     CrossRef
  • Risk assessment and management of post-transplant diabetes mellitus
    Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Metabolism.2016; 65(10): 1559.     CrossRef
Clinical Study
Association between Bsm1 Polymorphism in Vitamin D Receptor Gene and Diabetic Retinopathy of Type 2 Diabetes in Korean Population
Yong Joo Hong, Eun Seok Kang, Myoung Jin Ji, Hyung Jin Choi, Taekeun Oh, Sung-Soo Koong, Hyun Jeong Jeon
Endocrinol Metab. 2015;30(4):469-474.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.469
  • 3,618 View
  • 43 Download
  • 20 Citations
AbstractAbstract PDFPubReader   CrossRef-TDMCrossref - TDM
Background

Type 2 diabetes is one of the most common diseases with devastating complications. However, genetic susceptibility of diabetic complications has not been clarified. The vitamin D endocrine system is related with calcification and lipolysis, insulin secretion, and may be associated with many complicated disease including diabetes and cardiovascular disease. Recent studies reported that single nucleotide polymorphisms of vitamin D receptor (VDR) gene were associated with diabetic complications.

Methods

In present study, we evaluated the association of BsmI polymorphism of VDR with diabetic complications in Korean diabetes patients. Total of 537 type 2 diabetic subjects from the Endocrinology Clinic of Chungbuk National University Hospital were investigated. Polymerase chain reaction-restriction fragment length polymorphism was used to test the genotype and allele frequency of BsmI (rs1544410; BB, Bb, bb) polymorphisms.

Results

Mean age was 62.44±10.64 years and mean disease duration was 13.65±7.39 years. Patients with B allele (BB or Bb) was significantly associated with lower risk of diabetic retinopathy (severe non-proliferative diabetic retinopathy or proliferative retinopathy; 7.4%, 5/68) compared with patients without B allele (bb; 17.3%, 81/469; P=0.035). This association was also significant after adjusting for hemoglobin A1c level, body mass index, age, sex, and diabetes mellitus duration, concurrent dyslipidemia and hypertension (odds ratio, 2.99; 95% confidence interval, 1.08 to 8.29; P=0.035) in logistic regression analysis.

Conclusion

Our findings suggest that B allele of Bsm1 polymorphism in VDR gene is associated with lower risk of diabetic retinopathy in type 2 diabetic patients. Bsm1 genotype could be used as a susceptibility marker to predict the risk of diabetes complication.

Citations

Citations to this article as recorded by  
  • Metabolic impact of the VDR rs1544410 in diabetic retinopathy
    Caroline Severo de Assis, Tainá Gomes Diniz, João Otávio Scarano Alcântara, Vanessa Polyana Alves de Sousa Brito, Rayner Anderson Ferreira do Nascimento, Mayara Karla dos Santos Nunes, Alexandre Sérgio Silva, Isabella Wanderley de Queiroga Evangelista, Ma
    PLOS ONE.2022; 17(2): e0263346.     CrossRef
  • Vitamin D, the Vitamin D Receptor, Calcitriol Analogues and Their Link with Ocular Diseases
    Miłosz Caban, Urszula Lewandowska
    Nutrients.2022; 14(11): 2353.     CrossRef
  • Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease
    Paula González Rojo, Cristina Pérez Ramírez, José María Gálvez Navas, Laura Elena Pineda Lancheros, Susana Rojo Tolosa, María del Carmen Ramírez Tortosa, Alberto Jiménez Morales
    International Journal of Molecular Sciences.2022; 23(15): 8686.     CrossRef
  • Effects of Vitamin D Receptor Genotype on Lipid Profiles and Retinopathy Risk in Type 2 Diabetes Patients: A Pilot Study
    Hussam Alhawari, Yazun Jarrar, Dina Abulebdah, Sara J. Abaalkhail, Marah Alkhalili, Sura Alkhalili, Hussein Alhawari, Munther Momani, Mohammed N. Obeidat, Rand K. Fram, Mohammad A. Salahat, Su-Jun Lee
    Journal of Personalized Medicine.2022; 12(9): 1488.     CrossRef
  • Relation of vitamin D and BsmI variant with temporomandibular diseases in the Turkish population
    S. Yildiz, M.K. Tumer, S. Yigit, A.F. Nursal, A. Rustemoglu, Y. Balel
    British Journal of Oral and Maxillofacial Surgery.2021; 59(5): 555.     CrossRef
  • The relationship between vitamin D receptor (VDR) rs2228570 and rs7975232 genetic variants and the risk of recurrent pregnancy loss
    Zohreh Salari, Nasrollah Saleh-Gohari, Monire Rezapour, Ahamad Khosravi, Hadi Tavakkoli, Ehsan Salarkia, Fatemeh Karami-Robati
    Meta Gene.2021; 27: 100833.     CrossRef
  • Association of Bone Metabolism Indices and Bone Mineral Density with Diabetic Retinopathy in Elderly Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Inpatient Study in China
    Xin Zhao, Lili Huo, Xiaofeng Yu, Xiaomei Zhang, Fabio Vescini
    Journal of Diabetes Research.2021; 2021: 1.     CrossRef
  • The Associations Between Vitamin D Receptor BsmI and ApaI Polymorphisms and Obesity in Korean Patients with Type 2 Diabetes Mellitus
    Sang Won Nam, Jinwoo Choi, Hyun Jeong Jeon, Tae Keun Oh, Dong-Hwa Lee
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 557.     CrossRef
  • Vitamin D Deficiency at Mid-Pregnancy Is Associated with a Higher Risk of Postpartum Glucose Intolerance in Women with Gestational Diabetes Mellitus
    Kyung-Soo Kim, Seok Won Park, Yong-Wook Cho, Soo-Kyung Kim
    Endocrinology and Metabolism.2020; 35(1): 97.     CrossRef
  • The role of vitamin D in the pathogenesis and treatment of diabetes mellitus: a narrative review
    Maria Grammatiki, Spiros Karras, Kalliopi Kotsa
    Hormones.2019; 18(1): 37.     CrossRef
  • Vitamin D-binding protein and vitamin D receptor genotypes and 25-hydroxyvitamin D levels are associated with development of aortic and mitral valve calcification and coronary artery diseases
    Amir Kiani, Ehsan Mohamadi-Nori, Asad Vaisi-Raygani, Maryam Tanhapour, Said Elahi-Rad, Fariborz Bahrehmand, Zohreh Rahimi, Tayebeh Pourmotabbed
    Molecular Biology Reports.2019; 46(5): 5225.     CrossRef
  • Is Hypovitaminosis D Related to Incidence of Type 2 Diabetes and High Fasting Glucose Level in Healthy Subjects: A Systematic Review and Meta-Analysis of Observational Studies
    Shamaila Rafiq, Per Jeppesen
    Nutrients.2018; 10(1): 59.     CrossRef
  • Association between the vitamin D receptor gene polymorphisms and diabetic nephropathy risk: A meta‐analysis
    Fang Yin, Jing Liu, Ming‐Xiu Fan, Xiao‐Li Zhou, Xiao‐Ling Zhang
    Nephrology.2018; 23(2): 107.     CrossRef
  • BSMI single nucleotide polymorphism in vitamin D receptor gene is associated with decreased circulatory levels of serum 25-hydroxyvitamin D among micro and macrovascular complications of type 2 diabetes mellitus
    Krishnamoorthy Ezhilarasi, Umapathy Dhamodharan, Viswanathan Vijay
    International Journal of Biological Macromolecules.2018; 116: 346.     CrossRef
  • Diabetic macular oedema: under‐represented in the genetic analysis of diabetic retinopathy
    Suzanne Broadgate, Christine Kiire, Stephanie Halford, Victor Chong
    Acta Ophthalmologica.2018; 96(A111): 1.     CrossRef
  • Expression of JAZF1, ABCC8, KCNJ11and Notch2 genes and vitamin D receptor polymorphisms in type 2 diabetes, and their association with microvascular complications
    Maha A. Rasheed, Nagwa Kantoush, Nagwa Abd El-Ghaffar, Hebatallah Farouk, Solaf Kamel, Alshaymaa Ahmed Ibrahim, Aliaa Shalaby, Eman Mahmoud, Hala M. Raslan, Omneya M. Saleh
    Therapeutic Advances in Endocrinology and Metabolism.2017; 8(6): 97.     CrossRef
  • Vitamin D and diabetes mellitus: Causal or casual association?
    M. Grammatiki, E. Rapti, S. Karras, R. A. Ajjan, Kalliopi Kotsa
    Reviews in Endocrine and Metabolic Disorders.2017; 18(2): 227.     CrossRef
  • The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies
    Bang-An Luo, Fan Gao, Lu-Lu Qin
    Nutrients.2017; 9(3): 307.     CrossRef
  • The Association between VDR Gene Polymorphisms and Diabetic Retinopathy Susceptibility: A Systematic Review and Meta-Analysis
    Yun Zhang, Wei Xia, Ping Lu, Huijuan Yuan
    BioMed Research International.2016; 2016: 1.     CrossRef
  • Candidate gene studies of diabetic retinopathy in human
    Petra Priščáková, Gabriel Minárik, Vanda Repiská
    Molecular Biology Reports.2016; 43(12): 1327.     CrossRef
A Case of Latent Autoimmune Diabetes in Adults Developed after Surgical Cure of Growth Hormone Secreting Pituitary Tumor.
Wonjin Kim, Jung Ho Kim, Youngsook Kim, Ji Hye Huh, Su Jin Lee, Mi Sung Park, Eun Yeong Choe, Jeong Kyung Park, Myung Won Lee, Jae Won Hong, Byung Wan Lee, Eun Seok Kang, Bong Soo Cha, Eun Jig Lee, Hyun Chul Lee
Endocrinol Metab. 2012;27(4):318-322.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.318
  • 1,840 View
  • 29 Download
AbstractAbstract PDF
Acromegaly is generally caused by a benign growth hormone (GH)-secreting pituitary adenoma. It is characterized by a wide range of complications; cardiovascular, respiratory, bone and joint, and metabolic complications. Among them, impaired glucose tolerance and diabetes mellitus, due to GH-induced insulin resistance, has been reported in approximately 16-46% and 19-56%. They are usually improved following the treatment of acromegaly, surgical or medical therapy. We report a first case of 36-year-old man who was paradoxically diagnosed with GAD antibody positive latent autoimmune diabetes in adults (LADA) after the surgical cure of acromegaly.
Effect of 17-beta Estradiol on Adipocyte Lipin-1 Expression in OLETF Rat.
Eun Seok Kang, In Sook Kim, Seok Jin Ko, Chul Hoon Kim, Sung Wan Chun, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee
Endocrinol Metab. 2010;25(3):199-205.   Published online September 1, 2010
DOI: https://doi.org/10.3803/EnM.2010.25.3.199
  • 1,785 View
  • 21 Download
  • 1 Citations
AbstractAbstract PDF
BACKGROUND
17 beta-estradiol is known to play an important role in glucose homeostasis. Lipin-1 is a nuclear protein that is essential in adipocyte differentiation and it is considered to play a role in ectopic fat deposition and the redistribution of fat. The aim of this study was to evaluate the effect of 17 beta-estradiol on the lipin-1 expression in the adipocytes of OLETF rats, which is an animal model of diabetes. METHODS: The OLETF rats were divided into 3 groups, 1) the sham-operation group (SHAM) 2) the castrated group (CAST) and 2) the castrated and estradiol treatment group (EST), and all the rats were at 6 weeks of age. LETO rats were used as a control group (LETO). 0.1 mg of estradiol valerate was injected subcutaneously every 4 weeks in the rats of the EST group. The visceral and subcutaneous tissues were isolated to evaluate the lipin-1 protein expression. The lipin-1 expression was measured in human visceral and subcutaneous preadipocytes. RESULTS: Less body weight gain was observed in the EST group compared with that of the SHAM group. In addition, improvement in the glucose tolerance was observed in the EST group. The lipin-1 expression in visceral fat was decreased in the SHAM and CAST groups, but it was but recovered in the EST group. The lipin-1 expression in the subcutaneous fat was decreased in the SHAM, CAST, and EST groups. CONCLUSION: Long term estradiol treatment in OLETF rats reduces the body weight gain and improves the glucose tolerance. Estradiol enhances the lipin-1 protein expression in the visceral adipocytes, but not in the subcutaneous adipocytes.

Citations

Citations to this article as recorded by  
  • Effect of 17-beta Estradiol on Adipocyte Lipin-1 Expression in OLETF Rat
    Seong-Kyu Lee
    Endocrinology and Metabolism.2010; 25(3): 177.     CrossRef
Retraction: Contributing Factors to Different Natural Courses of Posttansplantation Diabetes Mellitus in Renal Allograft Recipients.
Kyu Yeon Hur, Myoung Soo Kim, Jae Hyun Nam, Eun Seok Kang, Hyun Joo Lee, So Hun Kim, Bong Soo Cha, Chul Woo Ahn, Soon Il Kim, Yu Seun Kim, Hyun Chul Lee
J Korean Endocr Soc. 2007;22(6):479.   Published online December 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.6.479
  • 1,378 View
  • 21 Download
PDF
A Case of Turner's Syndrome with Transient Hypopituitarism.
Ji Sun Nam, Min Ho Cho, Jung Min Roh, Hai Jin Kim, Ji Eun Yoon, Han Young Jung, Jong Suk Park, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
J Korean Endocr Soc. 2007;22(4):266-271.   Published online August 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.4.266
  • 1,569 View
  • 18 Download
AbstractAbstract PDF
Turner's syndrome is characterized by short stature and gonadal dysgenesis, and it is often associated with various systemic manifestations, such as cardiovascular, renal, thyroidal, gastrointestinal, and musculoskeletal disorders. Though very rare, it can also be accompanied by hypopituitarism. It is important to give a meticulous medical attention to short females with gonadal dysgenesis so that neither disease is neglected or gets delayed diagnosis. In this case, Turner's syndrome and hypopituitarism were diagnosed almost simultaneously, but hypopiuitarism was transient, and the normal pituitary function was recovered spontaneously without any treatment. Initial sella MRI showed mild congenital hypoplastic hypopituitarism, and combined pituitary function test was compatible with hypopituitarism, but after 5 years, though growth hormone deficiency was still present, otherwise normal pituitary function was noted without any change in MRI. Herein, we are reporting a case of Turner's syndrome with transient idiopathic hypopituitarism with the review of literature.
A Case of Autoimmune Hypoglycemia due to Insulin Antibody in Patient with End Stage Renal Disease.
Ji Ye Jung, Eun Seok Kang, Beom Seok Kim, Sung Wan Chun, Yumie Rhee, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Sung Kil Lim, Hyun Chul Lee
J Korean Endocr Soc. 2006;21(6):536-541.   Published online December 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.6.536
  • 1,488 View
  • 17 Download
AbstractAbstract PDF
Fasting hypoglycemia results from several mechanisms. Autoimmune hypoglycemia is one of the rare causes of hypoglycemia, and characterized by hyperinsulinemia, fasting hypoglycemia and the presence of autoantibodies to insulin or insulin receptor. We report here on a 64-year-old male patient with autoimmune hypoglycemia with end stage renal disease. He had no history of diabetes or insulin use. He had experienced several severe hypoglycemic events. The serum C-peptide level was 7.48 ng/mL and the insulin concentration was 115.4 micro U/mL when the fasting plasma glucose level was 88 mg/dL. The insulin to glucose ratio was 5.42, which suggested the presence of insulinoma. Yet the radiologic studies, including magnetic resonance cholangiopancreatography, endoscopic ultrasonography and selective calcium stimulated venous sampling revealed no evidence of insulinoma. The insulin autoantibody level was 62 micro U/mL. Therefore, we could diagnosis the autoimmune hypoglycemia. The hypoglycemia was treated with prednisolone and the patient recovered from this. His insulin level decreased to 21.11 micro U/mL and the insulin autoantibody level decreased to 34 micro U/mL. Hypoglycemia in the hemodialysis patients is not uncommon. One should bear in mind autoimmune hypoglycemia as one of the causes of hypoglycemia in patients with no history of diabetes.
Contributing Factors to Different Natural Courses of Posttansplantation Diabetes Mellitus in Renal Allograft Recipients.
Kyu Yeon Hur, Myoung Soo Kim, Jae Hyun Nam, Eun Seok Kang, Hyun Joo Lee, So Hun Kim, Bong Soo Cha, Chul Woo Ahn, Soon Il Kim, Yu Seun Kim, Hyun Chul Lee
J Korean Endocr Soc. 2006;21(5):373-381.   Published online October 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.5.373
  • 1,773 View
  • 21 Download
  • 2 Citations
AbstractAbstract PDF
BACKGROUND
New onset diabetes is a major complication after kidney transplantation. However, the natural course of posttransplantation diabetes mellitus (PTDM) remains unclear. The aim of this study was to demonstrate the detailed natural courses of PTDM according to the onset and persistency of hyperglycemia, and to investigate risk factors for development of different courses of PTDM in renal allograft recipients. METHODS: A total of 77 renal allograft recipients without previously known diabetes were enrolled and performed a serial 75 g oral glucose tolerance test at 0, 1, and 7 years after kidney transplantation. Patients were classified according to the onset and persistency of PTDM: early PTMD (E-PTDM), late PTDM (L-PTDM), persistent PTDM (P-PTDM), transient PTMD (T-PTDM), and non-PTDN (N-PTDM). RESULTS: The incidence of each group was as follows: E-PTDM, 39%; L-PTDM, 11.7%; P-PTDM, 23.4% T-PTDM, 15.6%; N-PTDM, 49.3%. Tacrolimus and female gender were associated with the development of E-PTDM. Among E-PTDM, age at transplantation was a high risk factor for the development of P-PTDM. Higher BMI at year1 was associated with the development of L-PTDM. CONCLUSION: Different risk factors were associated with various natural courses of PTDM. Since old age and female gender are not modifiable risk factors, it may be important to modify immunosuppressive therapy regimens for the prevention of E-PTDM and control of body weight for L-PTDM.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
    Jaehyun Bae, Youjin Kim, Yongin Cho, Minyoung Lee, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
    Transplantation Proceedings.2019; 51(10): 3444.     CrossRef
  • Post-transplantation Diabetes Mellitus
    Kun-Ho Yoon
    Journal of Korean Endocrine Society.2006; 21(5): 370.     CrossRef
The Relationship between the Leptin Concentration and the Small Dense Low Density Lipoprotein Cholesterol Concentration in Korean Type 2 Diabetic Patients.
Wan Sub Shim, Hae Jin Kim, Eun Seok Kang, Yu Mie Rhee, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha
J Korean Endocr Soc. 2006;21(4):319-327.   Published online August 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.4.319
  • 1,606 View
  • 18 Download
  • 2 Citations
AbstractAbstract PDF
BACKGROUND
Leptin has been suggested as a possible cause of atherosclerotic disease. The small dense low-density lipoprotein cholesterol (LDL-C) has also been regarded as a new surrogate marker in atherosclerotic disease. The aim of this study was to evaluate the relationship between the leptin concentration and the small dense LDL-C concentration in Korean type 2 diabetic patients. METHODS: One hundred-ninety one type 2 diabetic patients, who did not use any medication that could affect the concentration of lipid such as statin, fibrate, thiazolidinediones and corticosteroid, were enrolled in this study. We analyzed the relationship between leptin, the small dense LDL-C and the other metabolic parameters. RESULTS: The small dense LDL-C concentrations were higher in the group with the highest tertile of the leptin value, both in males and females than those patients in the group with the lowest tertile of the leptin value. The small dense LDL-C concentrations were also higher in the group with the highest tertile of leptin divided by the BMI value both in males and females than those patients in the group with the lowest tertile of the leptin value. The leptin concentration was positively correlated with the small dense LDL-C, total cholesterol, triglyceride, LDL-C, insulin and HOMAIR values after adjusting for age, gender and BMI. CONCLUSION: The association between leptin and small dense LDL-C could be a factor that explains the association between leptin and cardiovascular disease.

Citations

Citations to this article as recorded by  
  • Relationships among Serum Adiponectin, Leptin and Vitamin D Concentrations and the Metabolic Syndrome in Farmers
    Seo-Eun Yeon, Hee-Ryoung Son, Jung-Sook Choi, Eun-Kyung Kim
    Korean Journal of Community Nutrition.2014; 19(1): 12.     CrossRef
  • The Effect of Visceral Fat Area and Adipocytokines on Acute Myocardial Infarction: A Case-Control Study in Adult Korean Population
    Kang-Kon Lee, Young-Sung Suh, Keun-Sang Yum
    The Korean Journal of Obesity.2012; 21(1): 57.     CrossRef
A Case of Patient with Opioid-Induced Adrenocortical Insufficiency and Hypogonadism.
Hai Jin Kim, Chul Sik Kim, Jong Suk Park, Jina Park, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
J Korean Endocr Soc. 2006;21(3):257-260.   Published online June 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.3.257
  • 1,678 View
  • 17 Download
AbstractAbstract PDF
Opioids are known to decrease plasma cortisol and testosterone level in human and other mammals. Nowadays, opioid use is exponentially increasing, but little is known about its side effects. With the help of progressive human science, we can habit longer life and as result, are becoming more avid for healthy life. In this respect, analgesics play important role in maintaining good and healthy quality of life. For this reason, it is important to fully understand its side effects and handle it with special precaution. We are reporting a 22-year-old male who had been taken opioid analgesic for more than six years to relieve chronic, intractable headache. Then, his hormone test revealed hypogonadotropic hypogonadism combined with hypoadrenocorticotropic hypoadrenalism but showed no definite clinical features except for sexual frigidity. After two years of oxycodon discontinuation, we reevaluated that his hormone test, and all other laboratory tests returned to the normal range.
A Case of Multiple Endocrine Neoplasia Type 1 with Papillary Thyroid Carcinoma.
Hai Jin Kim, Chul Sik Kim, Hyun Chul Je, Jina Park, Jong Suk Park, Jee Hyun Kong, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee, Hang Suk Jang, Soon Won Hong
J Korean Endocr Soc. 2006;21(1):79-84.   Published online February 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.1.79
  • 1,529 View
  • 21 Download
  • 1 Citations
AbstractAbstract PDF
This is the first report of papillary thyroid carcinoma combined with multiple endocrine neoplasia type 1 (MEN 1). It is an hereditary syndrome characterized by neoplastic disorders such as pituitary adenoma, parathyroid adenoma or hyperplasia and pancreatic neuroendocrine tumor, such as gastrinoma just like in our case. But sometimes pheochromocytoma, mucosal ganglioneuromas, lipoma, forgut carcinoid and thyroid disease could be accompany the disease, but coincidental papillary thyroid carcinoma was never reported before in Korea. Herein we represent a 39-year-old woman who manifested typical features of MEN 1 with coincidental papillary thyroid carcinoma. Despite with definite family history of MEN 1, her genetic analysis of DNA had not found any germline mutation in MEN 1 gene. Unidentified culprit gene unable further genetic study of finding LOH (loss of heterogeneity) in 11q13, the possible explanation of papillary thyroid carcinoma as a new component of MEN 1. As we have experienced a case of MEN 1 combined with papillary thyroid carcinoma, we report it with the review of literature.

Citations

Citations to this article as recorded by  
  • A Case of Multiple Endocrine Neoplasia Type I with Atypical Clinical Course
    Yun Sun Choi, Youn Sun Bai, Bon Jeong Ku, Young Suk Jo, Young Kun Kim, Heung Kyu Ro, Minho Shong
    Journal of Korean Endocrine Society.2008; 23(4): 266.     CrossRef
A Case of Multiple Endocrine Neoplasia Type 1 with Mutation in MENIN Gene.
Se Eun Park, Eun Seok Kang, Hyun Joo Lee, So Hun Kim, Mi Young Do, Shin Ae Kang, Seung Jin Han, Hyeong Jin Kim, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Il Jin Kim, Hyun Chul Lee
J Korean Endocr Soc. 2005;20(1):71-77.   Published online February 1, 2005
DOI: https://doi.org/10.3803/jkes.2005.20.1.71
  • 1,768 View
  • 22 Download
  • 6 Citations
AbstractAbstract PDF
Multiple endocrine neoplasia type 1(MEN 1) is an autosomal dominantly inherited syndrome, characterized by the combined occurrence of tumors of the parathyroid glands, endocrine pancreas, and anterior pituitary gland. The MENIN gene, which is a kind of tumor suppressor gene, is located at the chromosomal locus 11q13. It consists of one untranslated exon and nine exons encoding the menin protein. We report a case of a 22-yearss-old woman with MEN type 1, who was proven to have a mutation in the MENIN gene. The patient was admitted because of repeated hypoglycemia. The fasting plasma glucose level was 32mg/dL. Seventy two hours fasting test showed an the insulin/glucose ratio as 0.33. Endoscopic ultrasonography detected multiple masses on the pancreas. The arterial -stimulated venous sampling(ASVS) with calcium showed sudden step up of insulin at the head and tail portions of the pancreas. The sellar MRI showed a pituitary mass that produced prolactin. Instead of a pathologic diagnosis from operational specimen, the genetic analysis revealed a mutation in the MENIN 1 gene(exon 2, 200~201insAGCCC).

Citations

Citations to this article as recorded by  
  • Genetic and Epigenetic Analysis in Korean Patients with Multiple Endocrine Neoplasia Type 1
    Yoon Jung Chung, Sena Hwang, Jong Ju Jeong, Sun Yong Song, Se Hoon Kim, Yumie Rhee
    Endocrinology and Metabolism.2014; 29(3): 270.     CrossRef
  • A Case of Familial Multiple Endocrine Neoplasia Type 1 with a Novel Mutation in theMEN1Gene
    Min Jung Kim, Eun Hee Kim, Mi-Seon Shin, Joo Hui Kim, Hee Kyung Na, Seong Joon Park, Sang Ah Lee, Eun Hee Koh, Woo Je Lee, Ki Ho Song, Joong-Yeol Park, Ki-Up Lee, Gu-Hwan Kim, Han-Wook Yoo, Min-Seon Kim
    Endocrinology and Metabolism.2011; 26(2): 171.     CrossRef
  • Somatic Mutational Analysis of MEN1 and Phenotypic Correlation in Sporadic Parathyroid Tumors
    Young Su Chae, Hee Jin Kim, Sun Wook Kim, Myung-Chul Chang
    Journal of the Korean Surgical Society.2009; 76(1): 15.     CrossRef
  • Multiple Endocrine Neoplasia Type 1 with Multiple Leiomyomas Linked to a Novel Mutation in the MEN1 Gene
    Heekyoung Choi, Sehyun Kim, Jae-Hoon Moon, Yoon Hee Lee, Yumie Rhee, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Kyung Rae Kim, Hyun Chul Lee, Seon Yong Jeong, Hyun Ju Kim, Sung-Kil Lim
    Yonsei Medical Journal.2008; 49(4): 655.     CrossRef
  • A Case of Familial Multiple Endocrine Neoplasia Type 1 with MEN1 Gene Mutation
    Young Eun Jo, Yong-Jun Choi, Yun Kyung Kim, Sang Mi Ahn, Sun Hye Jung, Hae Jin Kim, Dae Jung Kim, Kwan Woo Lee, Ji-Hee Hong, Seon-Yong Jeong, Hyon J Kim, Yoon-Sok Chung
    Journal of Korean Endocrine Society.2007; 22(1): 68.     CrossRef
  • A Case of Familial Multiple Endocrine Neoplasia with MEN1 Gene Mutation
    Hye-Young Sung, Yeon-Joo Chun, Hyeug Lee, Bum Jun Kwon, Kun Woo Park, Jung Min Lee, Sung Dae Moon, Sang Ah Chang, Je-Ho Han
    Journal of Korean Endocrine Society.2006; 21(6): 560.     CrossRef
Adiponectin Gene Polymorphism and Carotid Artery Intima-Media thickness in Type 2 Diabetes.
Eun Seok Kang, So Young Park, So Hun Kim, Hyun Joo Lee, Kyu Yeon Hur, Seung Jin Han, Se Eun Park, Hyeong Jin Kim, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee
J Korean Endocr Soc. 2005;20(1):29-39.   Published online February 1, 2005
DOI: https://doi.org/10.3803/jkes.2005.20.1.29
  • 1,635 View
  • 18 Download
AbstractAbstract PDF
BACKGROUND
The aim of this study was to examine the association between the common polymorphisms of the adiponectin gene(ACDC) and the intima-media thickness(IMT) of the common carotid arteries in type 2 diabetic patients. METHODS: The B mode ultrasound examination of carotid artery was performed on 133 type 2 diabetic patients. The carotid IMT was calculated using the Intimascope computer program. The SNP45 and SNP276 of the ACDC were examined. RESULTS: There was no significant difference in the carotid IMT among the SNP45 genotypes(0.66+/-0.18mm for TT, 0.71+/-0.12mm for TG and 0.64+/-0.15mm for GG, P=NS). Subjects carrying the SNP276 GG genotype had a markedly lower serum adiponectin concentration than those carrying the TT genotype(3.35+/-2.00microgram/mL vs. 4.98+/-2.24microgram/mL, P=0.029) The carotid IMT was significantly higher in patients with the SNP276 GG genotype than those with the TT genotype (0.70+/-0.17mm vs. 0.59+/-0.13mm, P=0.032). Patients with the +45GG/+276GG genotype combination showed significantly higher mean carotid IMT than the other genotype combinations(0.78+/-0.09mm vs. 0.71+/-0.15mm, P=0.013) CONCLUSIONS: These results suggest that the adiponectin gene, SNP276 is associated with the carotid IMT in type 2 diabetic patients. Further studies are will be needed to confirm these genotypephenotype associations.
A Case of Hypercalcemia Associated with Hepatic Tuberculosis.
So Young Park, Eun Seok Kang, So Hun Kim, Mi Young Do, Kyu Yeon Hur, Bong Soo Cha, Sung Kil Lim, Hyun Chul Lee, Sang Hoon Ahn, Young Myoung Moon, Young Nyun Park
J Korean Endocr Soc. 2004;19(1):64-68.   Published online February 1, 2004
  • 1,133 View
  • 18 Download
AbstractAbstract PDF
In this report, a 70-year-old female patient was detected with laboratory findings of hypercalcemia. The most common causes of hypercalcemia are primary hyperparathyroidism and malignant disease. Her laboratory tests did not show any evidence for neither primary hyperparathyroidism nor malignant diseases. Thus, granulomatous disease was suspected as the cause of the hypercalcemia. Liver MRI (magnetic resonance image) was performed on the subject, which suggested the presence of hepatic tuberculosis and sarcoidosis. Because the chest x-ray did not show a definite tuberculous lesion, we performed a laparoscopic liver biopsy for a final diagnosis. Findings from the biopsy specimen showed typical tuberculosis. After treatment with tuberculosis medication, hypercalcemia of the subject was resolved. Hypercalcemia is a well recognized as a possible complication of active pulmonary tuberculosis. But one should consider hepatic tuberculosis without pulmonary tuberculosis as a cause of hypercalcemia.
A Case of Bilateral Macronodular Adrenal Hyperplasia with Cushing's Syndrome Treated by Unilateral Adrenalectomy.
Si Hoon Lee, Kwang Eun Lee, Eun Seok Kang, Sang Su Chung, Dae Jung Kim, Yun Mi Jin, Bong Soo Cha, Sung Kil Lim, Hyun Chul Lee, Kap Bum Huh
J Korean Endocr Soc. 2002;17(4):596-602.   Published online August 1, 2002
  • 934 View
  • 20 Download
AbstractAbstract PDF
In order to differentiate the causes of Cushing's syndrome; whether it is pituitary or adrenal-dependent, a high dose dexamethasone suppression test is usually performed but this does not always correlated with the imaging diagnosis. We report a case of bilateral macronodular adrenal hyperplasia, which was thought to be independent to adrenocorticotrophin (ACTH) stimulation. At first we thought it was pituitary-dependent Cushing's syndrome, due to its suppression by high dose dexamethasone. However, we found no abnormal findings on the brain sella magnetic resonance image (MRI). A significant finding, however, we found bilateral adrenal masses on the abdominal computed tomography (CT). We performed percutaneous selective adrenal venous sampling (PSAVS), and confirmed hypercortisolism of the left adrenal mass only. Therefore, we decided to remove the left adrenal gland to preserve the residual function of the right adrenal gland. After the left adrenalectomy, the patient became normotensive, and their buffalo hump disappeared, and her 24 hour urinary free cortisol level returned to normal.
A Case of Metastatic Pulmonary Calcification in Primary Hyperparathyroidism.
Kwang Eun Lee, Hae Jin Kim, Si Hoon Lee, Sang Woon Bae, Eun Seok Kang, Hae Won Chung, Hye Sun Seo, Dae Jung Kim, Sang Soo Chung, Sun Jung Kim, Young Duk Song, Sung Kil Lim
J Korean Endocr Soc. 2002;17(4):583-588.   Published online August 1, 2002
  • 1,036 View
  • 21 Download
AbstractAbstract PDF
Metastatic calcification is the deposition of calcium, in previously normal tissue, as a result of elevated plasma calcium and phosphorus product levels and has been reported in patients with parathyroid adenoma, parathyroid carcinoma, hyperparathyroidism due to chronic renal failure, vitamin D intoxication, and osteolytic bone tumors, such as multiple myelomas. The lungs are the most common site of metastatic calcification. We have experienced metastatic pulmonary calcification in a case of primary hyperparathyroidism. A 55-year old woman was admitted due to general weakness. From the laboratory evaluation, hypercalcemia and excess production of parathyroid hormone (PTH) were noted. technetium-99m-labelled sestamibi scintigraphy indicated an intense uptake in the lower pole area of the left thyroid gland, suggestive of a parathyroid adenoma. A technetium-99m phosphate (99mTc-MDP) bone scan showed increased uptakes in both lungs. A parathyroid lobectomy was performed, and primary hyperparathyroidism, due to a parathyroid adenoma, was finally diagnosed. A follow-up 99mTc-MDP bone scan showed the disappearance of the metastatic pulmonary calcification, with the clinical symptoms and biochemical parameters normalizing after 6 months.

Endocrinol Metab : Endocrinology and Metabolism